Viking Therapeutics, Inc. Stock News

It's been a tough year for healthcare stocks. The broader industry has underperformed the market this year, at least as judged by major healthcare-focused exchange-traded funds, such as the Vanguard Health Care ETF.

Viking Therapeutics, Inc. (NASDAQ:VKTX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 3:20 PM EDT Company Participants Brian Lian - President, CEO & Director Conference Call Participants Michael Ulz - Morgan Stanley, Research Division Presentation Michael Ulz Equity Analyst All right. Good afternoon, everyone, and thanks for joining us at the Morgan Stanley Global H...

The market was less than impressed with the top-line results from Viking Therapeutics' (VKTX 1.73%) phase 2 trial of an oral formulation of its anti-obesity drug VK2735. The disappointment created the sense that the stock lacks any near-term catalysts -- phase 3 results from VK2735 in subcutaneous (injection) form aren't likely until 2027 -- and that the excitement around the stock was primaril...

Viking Therapeutics Shares Plummet Following Clinical Trial Data Release

Viking Therapeutics Faces Investor Scrutiny Following Mixed Obesity Drug Results

Viking Therapeutics (VKTX -1.12%) has intrigued investors over the past year and a half because it's involved in a potential David and Goliath story. Today, pharma giants Eli Lilly and Novo Nordisk dominate the weight loss drug market, and other big pharmas such as Pfizer are working to get in on this valuable space.

Viking Therapeutics: A Promising Pipeline Tempered by Tolerability Questions